Michel Vandevelde

H-PHAR SA was founded in 2002 to develop products based on Hubriphar SA 'Know How', in particular, a drug (Azodicarbonamide) inactivating the retroviral nucleocapside Protein 7 (NCp7) opening a new therapeutic route to treat mutated HIV resistant to the actual therapy combining at least three active medicinal products. H-Phar is a pharmaceutical research company that develops candidate drugs based on its own worldwide patented technology. Through, knowledge, creativity and integrity, H-Phar aims to preserve and improve human health by offering treatments to everyone everywhere. H-Phar is active in four operating areas include preclinical research focusing on the development of anti-viral applications of the so-called 'zinc finger ejector' in the domain of hemorrhagic fever (arenaviruses) and oncoviruses (HPV**), preclinical research focusing on the development of immune-modulator drugs inhibiting graft rejection, clinical development of an anti-HIV*drug based on a totally new mechanism of action, Vaccine evaluation of a dendritic cell loaded with HPH116 killed virus vaccine for immunological responses boost. H-Phar studies are compliant with OCDE Guidelines and ICH/GMP/GLP/GCP rules. H-Phar has build partnerships with opinion leaders in major institutions in Belgium, Europe and the US.